Interpace Biosciences (OTCMKTS:IDXG) Stock Price Up 351.4% – Time to Buy?

Interpace Biosciences, Inc. (OTCMKTS:IDXG)’s share price shot up 351.4% during trading on Friday. The stock traded as high as $6.4250 and last traded at $6.41. 4,734 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 7,196 shares. The stock had previously closed at $1.42.

Interpace Biosciences Stock Up 351.4%

The firm has a fifty day moving average price of $1.61 and a two-hundred day moving average price of $1.73. The stock has a market capitalization of $28.40 million, a P/E ratio of 80.12 and a beta of 0.61.

Interpace Biosciences (OTCMKTS:IDXG) last announced its quarterly earnings data on Monday, August 10th. The business services provider reported $0.01 EPS for the quarter. The company had revenue of $9.13 million for the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 145.40%.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc is a molecular diagnostics company focused on providing testing and pathology services that support the diagnosis and management of cancer and other complex diseases. The company’s tests are designed to help physicians assess disease risk, improve diagnostic confidence and guide treatment decisions.

Its portfolio has included molecular tests for thyroid nodules, pancreatic cysts and gastrointestinal conditions. Key offerings include ThyGeNEXT and ThyraMIR for evaluating thyroid nodules, as well as PancraGEN and PanDNA for assessing pancreatic cysts.